Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945 is registered in ClinicalTrials.gov with Oncorena AB as lead sponsor.

NCT NCT05287945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05287945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Lead sponsor
Oncorena AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 4, 2023
Completion date
December 31, 2027
Enrollment
75 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell